益生菌衍生微载体增强口服抗癌药物吸收不良的生物可用性
Hangeun Kim1, Seung-Su Lee2, Yenny Kim2
1Research and Development Center, Skin Biotechnology Center Co. Ltd., Yongin 17104, Republic of Korea.
International journal of pharmaceutics
|June 1, 2025
概括
一种新的益生菌衍生微载体 (PM) 系统可以增强口服吸收的抗癌药物,如多克索鲁比辛. 该系统提高了药物的生物可用性和抗瘤功效,为静脉注射提供了一个有希望的替代方案.
科学领域:
- 生物技术是生物技术.
- 药物输送系统 药物输送系统
- 药理学 药理学是指药理学的学科.
背景情况:
- 许多抗癌药物口服吸收不良,需要静脉注射 (IV).
- 静脉注射增加了严重副作用的风险.
- 需要新的药物输送系统来改善口服生物利用率并减少副作用.
研究的目的:
- 评估益生菌衍生微载体 (PM) 系统的有效性,以增强口服吸收吸收不良的抗癌药物.
- 评估通过PM系统输送的多克索鲁比辛和帕克利塔塞尔的生物可用性和抗瘤疗效.
- 在体内调查PM介导药物递送的机制.
主要方法:
- 开发并使用益生菌衍生微载体 (PM) 系统.
- 将多克索鲁比辛和帕克利塔克塞尔装入到PM系统中.
- 用口服给小鼠的PM药物配方.
- 在小鼠模型中测量了血清药物度和评估了抗瘤作用.
- 研究了肠道巨细胞在PM介导药物运输中的作用.
主要成果:
- 与单独口服药物相比,PM显著增加了多克索鲁比的口服吸收和血清水平.
- 在小鼠模型中,PM-doxorubicin表现出与IV doxorubicin相似的抗瘤疗效.
- 口服的PM-doxorubicin显示出显著的抗瘤作用,而单独口服的多克索鲁比辛则没有.
- 通过PM将 doxorubicin 输入血液中,由肠道巨细胞促进.
结论:
- 益生菌衍生微载体 (PM) 系统有效增强口服抗癌药物吸收不良的生物可用性.
- PM提供了一个有前途的策略,用于口服的挑战性药物,如多克索鲁比辛和帕克利塔克塞尔,可能减少与静脉注射相关的副作用.
- 该机制涉及与肠道巨细胞的相互作用,促进药物运输进入循环.
更多相关视频
07:53Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
11.1K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.9K
相关概念视频
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:06Carrier-Mediated Transport
317
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
317
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
182
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
182
01:23Factors Influencing Bioavailability: First-Pass Elimination
6.2K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.2K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K